Kenneth Johnson, PharmD, SVP Global
Development & Medical Affairs to retire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patient lives by
developing and commercializing innovative products across a range
of therapies, today announced that Dr. Anh Nguyen has joined Xeris
as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP,
Global Development and Medical Affairs who will retire April 1,
2025. Dr. Nguyen will develop and lead the entire product portfolio
vision and strategic direction for the Medical, Regulatory,
Preclinical and Clinical Development, and Pharmacovigilance
functions, reporting to John Shannon, Xeris’ CEO.
“We are pleased to have Anh return to Xeris as our first Chief
Medical Officer. Anh is an accomplished clinician-scientist and
biopharma executive dedicated to driving advancements in regulatory
strategy, clinical development, medical affairs, and commercial
launches,” said John Shannon, CEO of Xeris. “He brings his
forward-thinking leadership to Xeris at a time when we prepare to
embark in our Phase 3 development of XP-8121 and continue to drive
growth of our commercial portfolio, especially Recorlev®.”
Mr. Shannon continued, “We are fortunate that Ken has
strategically played an active role in finding his successor and
has graciously agreed to help and support in the transition of his
organization under the new leadership of Anh. Ken’s guidance and
support will undoubtedly ensure a smooth passing of the baton and
set the stage for continued success of the entire Medical,
Regulatory, Preclinical and Clinical Development, and
Pharmacovigilance functions.”
Dr. Nguyen brings an extensive wealth of clinical and leadership
experience to his role as CMO, leading the development of
first-in-class therapies including circular RNA-based oncology
treatments, gene-edited xenotransplants, immuno-oncology vaccines,
and allogeneic CAR-T therapies. Dr. Nguyen served as Vice President
and Therapeutic Sector Lead at Asklepios Biopharmaceutical
(AskBio), where he directed the IND clearance and early-phase
clinical trials of AAV gene therapies for neuromuscular rare
disease. Among his many achievements, Dr. Nguyen shaped clinical
and regulatory policies for breakthrough therapies while serving as
a medical officer at the NIH, FDA, and CMS. During his Robert Wood
Johnson Foundation Health Policy Fellowship serving on the US
Senate HELP Committee, Dr. Nguyen was a key contributor to the
landmark "21st Century Cures Act". He also led the establishment of
an ambulatory surgical service to expedite pediatric orphan disease
and oncology trials, earning the prestigious NIH Director's Award.
During his tenure at Xeris, Dr. Nguyen served as the program
medical lead for Gvoke®’s NDA and MAA approvals and multiple IND
clearances for endocrine and rare disease, including novel
endocrine drug co-formulations for diabetes, immunology, and
pediatric epilepsy. Dr. Nguyen received an MBA from University of
Chicago, a MD from Rutgers New Jersey Medical School, and completed
his residency and fellowship training in anesthesiology and
cardiovascular anesthesia at Massachusetts General Hospital,
Harvard Medical School.
“It has been an honor to be part of an exceptionally talented
team and a privilege to help lead Xeris through its evolution to a
commercial-stage biopharmaceutical company,” said Ken Johnson. “I’m
very proud of what we have accomplished and am confident that Dr.
Nguyen will lead Xeris to new levels of success.”
“I’m excited to help lead the scientific efforts at Xeris, to
collaborate and usher a new era of transformative therapies that
leverage our innovation and strategic partnerships, to redefine
patient care,” said Dr. Nguyen.
About Xeris Xeris (Nasdaq: XERS) is a growth-oriented
biopharmaceutical company committed to improving patient lives by
developing and commercializing innovative products across a range
of therapies. Xeris has three commercially available products:
Recorlev®, for the treatment of endogenous Cushing’s syndrome;
Gvoke®, a ready-to-use liquid glucagon for the treatment of severe
hypoglycemia; and Keveyis®, a proven therapy for primary periodic
paralysis. Xeris also has a pipeline of development programs led by
XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for
hypothyroidism, as well as multiple early-stage programs leveraging
Xeris’ technology platforms, XeriSol® and XeriJect®, for its
partners.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on X,
LinkedIn, or Instagram.
Forward-Looking Statements Any statements in this press
release other than statements of historical fact are
forward-looking statements. Forward-looking statements include, but
are not limited to, statements about future expectations, plans and
prospects for Xeris Biopharma Holdings, Inc., including the
development of its product portfolio vision and strategy for its
internal functions, the potential growth of its commercial
portfolio, and other statements containing the words “will,”
“would,” “continue,” “expect,” “should,” “anticipate” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on numerous assumptions
and assessments made in light of Xeris’ experience and perception
of historical trends, current conditions, business strategies,
operating environment, future developments, geopolitical factors
and other factors it believes appropriate. By their nature,
forward-looking statements involve known and unknown risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. The various factors
that could cause Xeris’ actual results, performance or
achievements, industry results and developments to differ
materially from those expressed in or implied by such
forward-looking statements, include, but are not limited to, its
financial position and need for financing, including to fund its
product development programs or commercialization efforts, whether
its products will achieve and maintain market acceptance in a
competitive business environment, its reliance on third-party
suppliers, including single-source suppliers, its reliance on third
parties to conduct clinical trials, the ability of its product
candidates to compete successfully with existing and new drugs, and
its and collaborators’ ability to protect its intellectual property
and proprietary technology. No assurance can be given that such
expectations will be realized and persons reading this
communication are, therefore, cautioned not to place undue reliance
on these forward-looking statements. Additional risks and
information about potential impacts of financial, operational,
economic, competitive, regulatory, governmental, technological, and
other factors that may affect Xeris can be found in Xeris’ filings
with the Securities and Exchange Commission, the contents of which
are not incorporated by reference into, nor do they form part of,
this communication. Forward-looking statements in this
communication are based on information available to us, as of the
date of this communication and, while we believe our assumptions
are reasonable, actual results may differ materially. Subject to
any obligations under applicable law, we do not undertake any
obligation to update any forward-looking statement whether as a
result of new information, future developments or otherwise, or to
conform any forward-looking statement to actual results, future
events, or to changes in expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250224024050/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Xeris Biopharma (NASDAQ:XERS)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
